Welcome to CDC stacks | Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs - 29339 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
Filetype[PDF-562.49 KB]


Details:
No Related Documents.
You May Also Like:
  1. Live Virus Vaccines Based on a Vesicular Stomatitis Virus (VSV) Backbone: Standardized Template with Key Considerations for a Risk/Benefit Assessment*
    Personal Author:
    Clarke, David K.; Hendry, R. Michael; Singh, Vidisha; Rose, John K.; Seligman, Stephen J.; Klug, Bettina; Kochhar, Sonali; Mac, Lisa Marie; Carbery, Baevin; Chen, Robert T;
    Corporate Author:
    For the Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
    Published:
    Jul 06 2016
    Source:
    Vaccine. 34(51):6597-6609.
    Description:
    The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety of live, recombinant viral vaccines incorporating genes from heterologous viral and other microbial pathogens in their genome (so-called "...
    File Type:
    Filetype[PDF - 397.88 KB]
  2. Postexposure Treatment of Marburg Virus Infection
    Personal Author:
    Geisbert, Thomas W.; Hensley, Lisa E.; Geisbert, Joan B.; Leung, Anders; Johnson, Joshua C.; Grolla, Allen; Feldmann, Heinz;
    Published:
    Jul 2010
    Source:
    Emerg Infect Dis. 16(7):1119-1122.
    Description:
    Rhesus monkeys are protected from disease when a recombinant vesicular stomatitis virus-based vaccine is administered 20-30 min after infection with Marburg virus. We protected 5/6 monkeys when this vaccine was given 24 h after challenge; 2/6 animals...
    File Type:
    Filetype[PDF - 264.90 KB]
  3. Single-Dose Replication-Defective VSV-based Nipah Virus Vaccines Provide Protection from Lethal Challenge in Syrian Hamsters
    Personal Author:
    Lo, Michael K.; Bird, Brian H.; Chattopadhyay, Anasuya; Drew, Clifton P.; Martin, Brock E.; Coleman, Joann D.; Rose, John K.; Nichol, Stuart T.; Spiropoulou, Christina F.;
    Published:
    Oct 30 2013
    Source:
    Antiviral Res. 101.
    Description:
    Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the...
    File Type:
    Filetype[PDF - 995.25 KB]
  4. Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
    Personal Author:
    Marzi, Andrea; Feldmann, Friederike; Geisbert, Thomas W.; Feldmann, Heinz; Safronetz, David;
    Published:
    Feb 2015
    Source:
    Emerg Infect Dis. 21(2):305-307.
    Description:
    We demonstrated that previous vaccination with a vesicular stomatitis virus (VSV)-based Lassa virus vaccine does not alter protective efficacy of subsequent vaccination with a VSV-based Ebola virus vaccine. These findings demonstrate the utility of V...
    File Type:
    Filetype[PDF - 315.95 KB]
  5. Coming Soon
    Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model
    Personal Author:
    Kainulainen, Markus H.; Spengler, Jessica R.; Welch, Stephen R.; Coleman-McCray, JoAnn D.; Harmon, Jessica R.; Klena, John D.; Nichol, Stuart T.; Albariño, César G.; Spiropoulou, Christina F.;
    Published:
    May 25 2018
    Source:
    J Infect Dis. 217(12):1957-1966.
    Description:
    Lassa fever is a viral zoonosis that can be transmitted from person to person, especially in the hospital setting. The disease is endemic to several countries in West Africa and can be a major contributor to morbidity and mortality in affected areas....
    Public Access
    Available on:
    May 25, 2019